Mechanism of action of Erdafitinib

Erdafitinib(Erdafitinib) is an anti-cancer drug with the trade nameBalversa. Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who harbor susceptible FGFR3 or FGFR2 genes due to changes in disease and progressed during or after at least one prior course of platinum-containing chemotherapy (including12 courses).

Erdafitinibworks by blocking the activity of an abnormal protein that signals cancer cells to multiply,which helps slow or stop the spread of cancer cells. Erdafitinib is a kinase inhibitor that binds to and inhibits the enzymatic activities of FGFR1, FGFR2, FGFR3, and FGFR4, based on in vitro data. Erdafitinibalso bindsRET, CSF1R, PDGFRA, PDGFRB, FLT4, KIT and VEGFR2. Erdafitinib inhibits FGFR phosphorylation and signaling and reduces cell viability in cell lines expressing FGFR genetic alterations (including point mutations, amplifications, and fusions). Erdafitinib has shown antitumor activity in cell lines expressing FGFR and in xenograft models derived from tumor types (including bladder cancer).

Erdafitinib is the active ingredient in BALVERSA and is a kinase inhibitor. The chemical name is N-(3, 5-dimethoxyphenyl)-N '-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazole-4-yl)quinoxaline< /span>-6-yl]ethane-1, 2-diamine. Erdafitinib is a yellow powder. It is almost insoluble, or insoluble, or easily soluble in organic solvents, and is slightly soluble, almost insoluble, or insoluble in aqueous media with various pH values. The molecular formula is c25h 30N 6O 2, and the molecular weight is 446.56. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0